PMID- 10508479
OWN - NLM
STAT- MEDLINE
DCOM- 19991118
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 83
IP  - 4
DP  - 1999 Nov 12
TI  - Antigens recognized by autologous antibody in patients with renal-cell carcinoma.
PG  - 456-64
AB  - The screening of cDNA expression libraries derived from human tumors with
      autologous antibody (SEREX) is a powerful method for defining the structure of
      tumor antigens recognized by the humoral immune system. Sixty-five distinct
      antigens (NY-REN-1 to NY-REN-65) reactive with autologous IgG were identified by 
      SEREX analysis of 4 renal cancer patients and were characterized in terms of cDNA
      sequence, mRNA expression pattern, and reactivity with allogeneic sera. REN-9,
      -10, -19, and -26 have a known association with human cancer. REN-9 (LUCA-15) and
      REN-10 (gene 21) map to the small cell lung cancer tumor suppressor gene locus on
      chromosome 3p21.3. REN-19 is equivalent to LKB1/STK11, a gene that is defective
      in Peutz-Jeghers syndrome and cancer. REN-26 is encoded by the bcr gene involved 
      in the [t(9:22)] bcr/abl translocation. Genes encoding 3 of the antigens in the
      series showed differential mRNA expression; REN-3 displays a pattern of
      tissue-specific isoforms, and REN-21 and REN-43 are expressed at a high level in 
      testis in comparison to 15 other normal tissues. The other 62 antigens were
      broadly expressed in normal tissues. With regard to immunogenicity, 20 of the 65 
      antigens reacted only with autologous sera. Thirty-three antigens reacted with
      sera from normal donors, indicating that their immunogenicity is not restricted
      to cancer. The remaining 12 antigens reacted with sera from 5-25% of the cancer
      patients but not with sera from normal donors. Seventy percent of the renal
      cancer patients had antibodies directed against one or more of these 12 antigens.
      Our results demonstrate the potential of the SEREX approach for the analysis of
      the humoral immune response against human cancer.
CI  - Copyright 1999 Wiley-Liss, Inc.
FAU - Scanlan, M J
AU  - Scanlan MJ
AD  - Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering
      Cancer Center, New York, New York 10021, USA. scanlanm@mskcc.org
FAU - Gordan, J D
AU  - Gordan JD
FAU - Williamson, B
AU  - Williamson B
FAU - Stockert, E
AU  - Stockert E
FAU - Bander, N H
AU  - Bander NH
FAU - Jongeneel, V
AU  - Jongeneel V
FAU - Gure, A O
AU  - Gure AO
FAU - Jager, D
AU  - Jager D
FAU - Jager, E
AU  - Jager E
FAU - Knuth, A
AU  - Knuth A
FAU - Chen, Y T
AU  - Chen YT
FAU - Old, L J
AU  - Old LJ
LA  - eng
SI  - GENBANK/AF155095
SI  - GENBANK/AF155096
SI  - GENBANK/AF155097
SI  - GENBANK/AF155098
SI  - GENBANK/AF155099
SI  - GENBANK/AF155100
SI  - GENBANK/AF155101
SI  - GENBANK/AF155102
SI  - GENBANK/AF155103
SI  - GENBANK/AF155104
SI  - GENBANK/AF155105
SI  - GENBANK/AF155106
SI  - GENBANK/AF155107
SI  - GENBANK/AF155108
SI  - GENBANK/AF155109
SI  - GENBANK/AF155110
SI  - GENBANK/AF155111
SI  - GENBANK/AF155112
SI  - GENBANK/AF155113
SI  - GENBANK/AF155114
SI  - GENBANK/AF155115
SI  - GENBANK/AF155116
SI  - GENBANK/AF155117
SI  - GENBANK/AF155118
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Aged
MH  - Antibodies, Neoplasm/*metabolism
MH  - Antibody Specificity
MH  - Antigens, Neoplasm/biosynthesis/*genetics/*immunology/isolation & purification
MH  - Blotting, Northern
MH  - Carcinoma, Renal Cell/genetics/*immunology
MH  - Chromosome Mapping
MH  - Female
MH  - Gene Library
MH  - Humans
MH  - Kidney Neoplasms/genetics/*immunology
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/immunology
MH  - Organ Specificity
MH  - RNA, Messenger/biosynthesis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Serologic Tests
MH  - Tumor Cells, Cultured
EDAT- 1999/10/03 00:00
MHDA- 1999/10/03 00:01
CRDT- 1999/10/03 00:00
PHST- 1999/10/03 00:00 [pubmed]
PHST- 1999/10/03 00:01 [medline]
PHST- 1999/10/03 00:00 [entrez]
AID - 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5 [pii]
PST - ppublish
SO  - Int J Cancer. 1999 Nov 12;83(4):456-64.